Business
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
DURHAM, N.C., April 22, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will present new clinical biopsy data from the ongoing Phase 1 ELIMINATE-B trial during a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The ELIMINATE-B trial is evaluating PBGENE-
About this update from Precision Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/94a0f2e776ad71ea08601196faa2eb17"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H7rf8sB.AhEic0kuoRELCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/94a0f2e776ad71ea08601196faa2eb17","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/wWMAEcx92_LX5KV83JFasQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/94a0f2e776ad71ea08601196faa2eb17","width":1024,"height":512}},"lazy":false},{"type":"text","content":"- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B -","length":185,"tagName":"p","attribs":{}},{"type":"text","content":"DURHAM, N.C., April 22, 2026--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will present new clinical biopsy data from the ongoing Phase 1 ELIMINATE-B trial during a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The ELIMINATE-B trial is evaluating PBGENE-HBV for the treatment of chronic hepatitis B. The EASL Congress 2026 is being held May 27-30, 2026, in Barcelona, Spain.","length":637,"tagName":"p"},{"type":"text","content":"Title: First evidence of elimination and inactivation of cccDNA in liver biopsies collected from patients with chronic hepatitis B treated with PBGENE-HBV","length":154,"tagName":"p"},{"type":"text","content":"Presenter: Man-Fung Yuen Session: Late-Breaker PostersAbstract number: LB26-51656Presentation Number: LBP-043Date: May 27, 2026Time: 8:30 CEST","length":147,"tagName":"p"},{"type":"text","content":"About PBGENE-HBV, A Viral Elimination Program","length":45,"tagName":"p"},{"type":"text","content":"PBGENE-HBV is Precision’s wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for...